Table 4.
Outcome | No. | Events | HR (95% CI) | P value |
---|---|---|---|---|
OS | ||||
PTCY | 166 | 65 | ||
ATG | 597 | 301 | 1.32 (1-1.74) | .05 |
PFS | ||||
PTCY | 165 | 75 | ||
ATG | 595 | 328 | 1.33 (1.03-1.73) | .03 |
GRFS | ||||
PTCY | 162 | 102 | ||
ATG | 580 | 392 | 1.24 (0.99-1.56) | .06 |
NRM | ||||
PTCY | 165 | 40 | ||
ATG | 595 | 184 | 1.39 (0.97-2.01) | .07 |
Relapse/progression | ||||
PTCY | 165 | 35 | ||
ATG | 595 | 144 | 1.29 (0.88-1.88) | .2 |
aGVHD grade 2-4 | ||||
PTCY | 164 | 41 | ||
ATG | 575 | 197 | 1.61 (1.12-2.33) | .01 |
cGVHD | ||||
PTCY | 155 | 56 | ||
ATG | 578 | 224 | 1.06 (0.77-1.47) | .7 |
Effect estimates are given with 95% CI and corresponding P values were calculated using the Wald test.